Interactions with hormonal contraception

Elliman, Alyson

doi:10.1783/147118900101194193

Cited by 11 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[84][85][86] The most commonly used COC containing 50 µg EE (Ovran ® , Wyeth Laboratories) was discontinued in 2002. An alternative preparation containing 50 µg mestranol (Norinyl-1 ® , Pharmacia) is available.…”

Section: Liver Enzyme-inducing Drugsmentioning

confidence: 99%

FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence

2005

j fam plann reprod health care

View full text Add to dashboard Cite

This Guidance provides information for clinicians and women considering the use of contraception outside the terms of the product licence. A key to the grades of recommendations, based on levels of evidence, is given at the end of this document. Details of the methods used by the Clinical Effectiveness Unit (CEU) in developing this Guidance and evidence tables summarising the research basis of the recommendations are available on the Faculty website (www.ffprhc.org.uk). Abbreviations (in alphabetical order) used include: CEU, Clinical Effectiveness Unit; COC, combined oral contraception/contraceptive; DMPA, depot medroxyprogesterone acetate; ENG, etonogestrel; IUD, copper-bearing intrauterine contraceptive device; LNG-IUS, levonorgestrel-releasing intrauterine system; NET-EN, norethisterone enantate; PGD, Patient Group Direction; PIL, Patient Information Leaflet; POC, progestogen-only contraception/contraceptive; POEC, progestogen-only emergency contraception; POP, progestogen-only pill; RCT, randomised controlled trial; SPC, Summary of Product Characteristics; UPSI, unprotected sexual intercourse; WHO, World Health Organization; WHOMEC, WHO Medical Eligibility Criteria for Contraceptive Use; WHOSPR, WHO Selected Practice Recommendations for Contraceptive Use.

show abstract

Section: Liver Enzyme-inducing Drugsmentioning

confidence: 99%

FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence

2005

j fam plann reprod health care

View full text Add to dashboard Cite

show abstract

“…For example, mestranol is metabolised to EE; desogestrel is metabolised to 3-ENG; norgestimate is in part metabolised to levonorgestrel; and ethynodiol diacetate is metabolised to norethisterone. 1 EE is metabolised in the mucosa of the small intestine and in the liver, forming sulphate and glucuronide conjugates ( Figure 1). …”

Section: Metabolismmentioning

confidence: 99%

“…1,11,25,107,108 Despite lack of evidence, in the light of the potentially serious sequelae of unintended pregnancy, women are advised to use additional contraception, such as condoms, during use of a liver enzyme-inducing drug and for 28 days after the liver enzyme-inducer is stopped. 25,11 The most commonly used COC containing 50 µg EE (Ovran ® ) was discontinued in 2002.…”

Section: Women Using Even Short Courses Of Rifampicin (For Prophylaximentioning

confidence: 99%

See 1 more Smart Citation

FFPRHC Guidance (April 2005) Drug interactions with hormonal contraception

2005

j fam plann reprod health care

View full text Add to dashboard Cite

This Guidance provides information for clinicians and women using hormonal contraception applicable when concurrent medications are prescribed. A key to the grades of recommendations, based on levels of evidence, is given at the end of this document. Details of the methods used by the Clinical Effectiveness Unit (CEU) in developing this Guidance and evidence tables summarising the research basis of the recommendations are available on the Faculty website (www.ffprhc.org.uk). Abbreviations (in alphabetical order) used include:

show abstract

“…A Faculty Aid to Continuing Professional Development Topics (FACT) from the FFPRHC covers interactions with hormonal contraception. 11 In current practice, women taking drugs that may induce liver enzymes are often given DMPA every 10 weeks. The FACT cites the SPC for DMPA, 12 which suggests that no time adjustment is required for the injection interval since the contraceptive hormone is cleared at a rate equal to hepatic blood flow, and is not increased by liver enzyme-inducers.…”

Section: St John's Wortmentioning

confidence: 99%